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Abstract
Purpose—Indirect evidence from experimental and epidemiological studies suggests that
prolactin may be involved in ovarian cancer development. However, the relationship between
circulating prolactin levels and risk of ovarian cancer is unknown.
Methods—We conducted a nested case-control study of 230 cases and 432 individually-matched
controls within three prospective cohorts to evaluate whether pre-diagnostic circulating prolactin
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is associated with subsequent risk of ovarian cancer. We also assessed whether lifestyle and
reproductive factors are associated with circulating prolactin among controls.
Results—Prolactin levels were significantly lower among post- vs. pre-menopausal women,
parous vs. nulliparous women, and past vs. never users of oral contraceptives in our cross-
sectional analysis of controls. In our nested case-control study, we observed a non-significant
positive association between circulating prolactin and ovarian cancer risk (ORQ4vsQ1: 1.56, 95%
CI: 0.94, 2.63, p-trend: 0.15). Our findings were similar in multivariate-adjusted models and in the
subgroup of women who donated blood ≥5 years prior to diagnosis. We observed a significant
positive association between prolactin and risk for the subgroup of women with BMI ≥25 kg/m2
(ORQ4vsQ1: 3.10, 95% CI: 1.39, 6.90), but not for women with BMI <25 kg/m2 (ORQ4vsQ1: 0.81,
95% CI: 0.40, 1.64).
Conclusions—Our findings suggest that prolactin may be associated with increased risk of
ovarian cancer, particularly in overweight/obese women. Factors associated with reduced risk of
ovarian cancer, such as parity and use of oral contraceptives, were associated with lower prolactin
levels, which suggests that modulation of prolactin may be a mechanism underlying their
association with risk.
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Background
The polypeptide hormone prolactin has numerous functions in addition to its important role
in lactation, including a role in reproduction (i.e., maintaining normal ovarian function and
modulating the effects of gonadotropins) and modulating immune function [1, 2]. Though
prolactin is primarily produced in the pituitary gland it is also produced in other tissues,
including the ovaries [1]. The prolactin receptor is expressed in normal ovarian and fallopian
tube tissues [1, 3, 4], the primary sites of origin for ovarian tumors. There are several ways
that prolactin could influence ovarian cancer development. Animal and in vitro studies have
shown that prolactin promotes growth of ovarian surface epithelial cells and inhibits
apoptosis and increases survival of ovarian cancer cells [5-8]. Furthermore, prolactin levels
increase in response to psychosocial and physical stress [9], which was associated with
greater tumor burden and tumor invasiveness in a mouse model of ovarian cancer [10, 11].
In cross-sectional studies, known risk factors for ovarian cancer (e.g. nulliparity and
endometriosis) were associated with higher prolactin levels [12, 13], which suggests that
prolactin may be part of the underlying mechanism through which these factors influence
risk. Prolactin receptor expression and circulating prolactin levels have been shown to be
higher among women with ovarian cancer vs. benign-condition or healthy controls [6, 14,
15]. However, a major limitation of these retrospective studies is that prolactin levels may
have been affected by the presence of the tumor and/or the stress associated with cancer
diagnosis or treatment. Thus, the purpose of this study was to assess prospectively the
relationship between pre-diagnostic circulating levels of prolactin and subsequent risk of
invasive ovarian cancer. We also performed a cross-sectional analysis in controls to examine
factors associated with prolactin levels.
Methods
We conducted a nested case-control study within three prospective cohorts, the NYU
Women’s Health Study (NYUWHS), the Northern Sweden Health and Disease Study
(NSHDS), and the ORDET cohort in Italy. These parent cohorts and nested case-control
study of epithelial ovarian cancer have been described previously [16]. In total, 230 ovarian
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cancer cases and 432 controls (~2 per case matched on age, menopausal status, and date of
blood sampling) were included. Prolactin was measured using Luminex Xmap multiplex
bead-based technology using a kit from Linco/Millipore according to the manufacturer’s
instructions. All prolactin values were above the limit of detection of the assay. Blinded
replicates from a serum pool were used for quality control and were interspersed at random
on each plate. The intra- and inter-batch coefficients of variation for prolactin were ≤ 1%.
Prolactin values were log transformed to reduce departure from the normal distribution.
Seven outliers (3 cases and 4 controls) were identified using the generalized extreme
Studentized deviate many-outlier procedure described by Rosner [17]. Removal of these
outliers did not change the results appreciably. To assess the relationship between lifestyle/
reproductive factors and prolactin levels, we performed a cross-sectional analysis in the
controls, using generalized estimating equations to calculate geometric means adjusted for
cohort and age (continuous), taking into account the correlation between controls from the
same matched set. We also performed cross-sectional analyses mutually adjusted for all
factors significantly associated with prolactin levels in our study (age, parity, oral
contraceptive use, and menopausal status). To examine the association between prolactin
levels and ovarian cancer risk, conditional logistic regression, which takes into account the
risk set sampling and matching factors (age, menopausal status, and sample storage time),
was used to estimate odds ratios across quartiles of prolactin. Quartile cut points were based
on the cohort-specific distribution of values in the cases and controls combined. Multivariate
conditional logistic regression models were adjusted for parity (ever/never had a full term
pregnancy) and use of oral contraceptives (OCs, past/never). There were no current users of
OCs because the study eligibility criteria required that women were not using any exogenous
hormones (OCs or hormone replacement therapy) at the time of blood donation. Missing
data for parity (9.2% of women) and OC use 14.4% of women) were imputed for each
cohort separately using a fully conditional specification (FCS) multiple imputation method
[18], as appropriate for the imputation of missing categorical variables, adjusted for case-
control status. Other known and suspected risk factors for ovarian cancer, including family
history of breast or ovarian cancer and body mass index (BMI), were not included in the
final model because they were not associated with prolactin levels and their inclusion did
not affect the odds ratio estimates appreciably (<10% change in the odds ratios) (data not
shown). To test for cohort heterogeneity, we compared the model with the cross product
term (prolactin × cohort) to the model without this term using the likelihood ratio test, and
we also used the Q statistic. To increase the effective sample size for the analysis stratified
by BMI, OC use, and parity, we broke the case-control matching and controlled for the
matching factors in unconditional logistic regression models, after verifying that these two
methods produced very similar odds ratios.
Results
Characteristics of cases and controls are shown in Table 1. The median age at blood
sampling (at the time of cohort enrollment) was 55 years. The time between blood donation
and diagnosis was ≥5 years for 65% of cases. Although differences were not statistically
significant, cases were more likely to have a family history of breast or ovarian cancer (23%
vs. 15%, p=0.07), more likely to be nulliparous (23% vs. 18%, p=0.17), and less likely to
have used OCs (64% vs. 70%, p=0.26), as expected.
Table 2 shows the geometric mean prolactin by categories of lifestyle and reproductive
factors. In cohort-adjusted models, prolactin levels decreased significantly with age (p-trend
≤ 0.001). Adjusting for age and cohort, prolactin was lower among post-vs. pre-menopausal
women (13.3 vs. 17.8, p ≤ 0.001), ever-parous vs. nulliparous women (14.3 vs. 17.0, p =
0.01), and past vs. never users of OCs (13.6 vs. 15.5, p=0.03). Simultaneous adjustment for
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all of the factors that were significantly associated with prolactin levels (i.e., age,
menopausal status at enrollment, parity, and use of OCs), did not change the geometric
means appreciably, though the trend by age was no longer significant due to adjustment for
menopausal status (p-trend = 0.08, p-value for difference between means = 0.03). The
association between prolactin and all reproductive and lifestyle factors was similar for pre-
and post-menopausal women in stratified analyses (data not shown).
Odds ratios and 95% confidence intervals showing the relation between prolactin levels and
ovarian cancer risk are presented in Table 3. We observed a modest increase in risk for the
highest vs. the lowest quartile of prolactin in unadjusted analyses (OR for the highest vs.
lowest quartile: 1.56, 95% confidence interval: 0.94, 2.63), though the association and test
for trend across quartiles (p = 0.15) was not statistically significant. Results were similar
after adjustment for parity (ever/never) and OC use (past/never). Among the subgroups of
women with more detailed information about number of full term pregnancies, age at first
full term pregnancy, and duration of OC use, adjustment for these variables did not result in
an appreciable change in the ORs compared with models adjusted for dichotomized parity
(ever/never) and OC use (past/never). The test for heterogeneity by cohort was not
significant (p=0.33 for both the likelihood ratio and Q tests). We observed a significant trend
of increasing risk across quartiles of prolactin in the subgroup of women with BMI ≥25 kg/
m2 (ORQ4vQ1: 3.10, 95% CI: 1.39, 6.90, p-trend=0.01), but no association for women with
BMI <25 kg/m2 (ORQ4vQ1: 0.81, 95%CI: 0.40, 1.64, p-trend=0.46, p-interaction = 0.06;
Table 3). Odds ratios for prolactin were not appreciably different in subgroups defined by
menopausal status at enrollment (pre/post), parity (nulliparous/parous), or OC use (past/
never). There was no evidence of interaction by time to diagnosis (<5/≥5 years after blood
donation). The association between prolactin and risk in analyses restricted to women with
the serous tumor subtype was in the same direction as the overall results.
Discussion
In this prospective case-control study nested within three cohorts, we observed a non-
significant trend of increasing risk of ovarian cancer across quartiles of circulating prolactin.
Odds ratios were similar for women who were diagnosed five or more years after blood
donation, suggesting that the association we observed was not due to the effect of disease on
prolactin levels. Results for the subgroup of women with the serous histological tumor
subtype were also in the same direction as the overall results. Prolactin was significantly
associated with ovarian cancer risk for women with BMI ≥ 25 kg/m2, but not for women
with lower BMI (p-interaction=0.06).
In our cross-sectional analysis in controls, we confirmed that prolactin is inversely
associated with age. Consistent with the literature, we found that prolactin levels were lower
in post-menopausal vs. premenopausal women [13, 19-21] and among parous vs. nulliparous
women [13, 20, 22-31], and that prolactin levels did not vary by age at first birth [13, 20, 24,
27, 30, 31] or age at menarche [13, 27, 29].
To our knowledge, only two previous studies have assessed the relationship between history
of OC use and prolactin levels: premenopausal [31], but not postmenopausal [27], ever users
of OCs were shown to have lower prolactin levels than never users. In our study, past use of
OCs was associated with lower prolactin levels in both pre- and post-menopausal women.
Many changes in OC formulations have occurred over time and there are numerous
formulations on the market with varied doses and types of estrogens and progestins, thus it
is difficult to compare results across studies. If OC use is associated with reduced prolactin
levels, as our data and that of Wang, et al [31] suggest, this may partially explain the
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consistent protective effect of OC use on ovarian cancer risk, though further studies are
needed to assess this mechanism.
Though women with a family history of breast and/or ovarian cancer had higher prolactin
levels in some studies [13, 32-35], most studies [20, 22, 27, 31, 36-39], including ours, did
not observe any difference in prolactin among women with vs. without a family history.
Prolactin and the prolactin receptor are expressed in ovarian and fallopian tube tissues and
are involved in physiological ovarian processes, such as follicle development and corpus
luteum function, during the menstrual cycle as well as pregnancy [1, 3, 4]. Experimental
evidence suggests that increased prolactin signaling, through upregulation of the prolactin
receptor, may play a role in promoting cancer development by increasing cell proliferation,
reducing apoptosis, and modulating immune function [1, 5, 6]. Other carcinogenic
mechanisms of prolactin have been suggested, including increased angiogenesis and cell
motility as well as cross-talk with inflammatory mediators [reviewed in [6]]. Several
retrospective studies have reported higher levels of circulating prolactin among women with
ovarian cancer vs. benign-condition or healthy controls [6, 14, 15]. To our knowledge, no
other prospective studies have assessed the relationship between pre-diagnostic circulating
prolactin and subsequent risk of ovarian cancer. Our results suggest that prolactin may be
associated with increased risk of ovarian cancer, although the odds ratios and tests for trend
across quartiles were not significant.
We observed that prolactin was significantly associated with risk for women with BMI ≥ 25
kg/m2, but not for women with BMI <25 kg/m2, in models adjusted for age, menopausal
status, parity, OC use, and BMI. Obesity is considered to be a low grade chronic
inflammatory state [40], thus high prolactin levels among women with higher BMI may act
in combination with increased levels of inflammation mediators to modulate immune
function [1, 2] and contribute to ovarian cancer development. Despite the biological
plausibility of our finding, our BMI subgroup analysis was based on a fairly small number
of women, and the association may be due to chance. The distribution of ovarian cancer
histological subtypes in each BMI subgroup was similar.
A limitation of our study is that circulating levels of prolactin may not reflect local levels in
ovarian cancer tissues of origin, i.e., the ovaries and fallopian tubes. Local prolactin levels
may be a more relevant exposure because prolactin can act as both an endocrine and
paracrine signaling molecule [1]. Measuring prolactin levels in the ovaries or fallopian
tubes, though, is not an option in prospective studies of healthy subjects such as ours.
However, data on the correlation between local and circulating prolactin levels from other
studies, for instance in women undergoing tubal ligation, would help interpret the results of
studies on circulating levels. Furthermore, several prolactin receptor isoforms have been
identified in the ovaries and the varied expression and dimerization of these receptors may
influence the effects of the prolactin ligand on ovarian cancer risk [41]. Studies have shown
that there are also several variant forms of prolactin [42, 43]. Our immunoassay was not able
to distinguish between the different isoforms or structural variants of prolactin which may
have different bioavailabilities and biological actions. However, the prolactin variant(s)
most likely to be relevant to ovarian cancer development have not yet been identified.
We only had one measurement of prolactin for each woman. However, we observed high
temporal reliability (intra-class correlation coefficient of ~0.6-0.7 in serum and plasma) in
paired serum samples from the NYUWHS cohort (n=65 pairs) and plasma samples from the
NSHDS cohort (n=18 pairs), collected from the same women over a 2-3 year period ([44]
and unpublished data). These results indicate that a single prolactin measurement is
representative of a woman’s average level over a few years’ time. The fairly high ICCs,
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despite the fact that we did not control for the effects of time of day of sample collection,
fasting status, and medication use, which have been shown to affect levels of prolactin [31,
45-48], suggest that the intra-subject variability due to these factors is not large, relative to
the between subject variability. Although one study reported low reproducibility for
prolactin among premenopausal women in the luteal phase of the menstrual cycle (ICC:
0.41) [48] and another reported low reproducibility among pre-(ICC: 0.40) and post-
menopausal (ICC: 0.18) women [49], most other studies have reported high reproducibility
estimates (ICC range: 0.53-0.76) for pre- and post-menopausal women similar to the present
study [48, 50, 51], including an earlier study within the NYUWHS cohort that used a
different assay method [50].
In summary, we observed a modest positive association between prolactin and risk of
ovarian cancer, though it was not statistically significant except for the subgroup of women
with BMI ≥ 25 kg/m2. Consistent with the literature, we observed an inverse association
between prolactin levels and both parity and OC use, suggesting that reduced prolactin
secretion may be one mechanism underlying the inverse association between these factors
and ovarian cancer risk.
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Table 1
Characteristics of ovarian cancer cases and matched controls, NYUWHS, NSHDS, and ORDET
Characteristics Cases (N=230) Controls (N=432) p-value
Age at blood sampling, y, n (%)
 ≤45 years 48 (20.9) 90 (20.9)
 46-55 years 73 (31.7) 134 (31.1)
 >55 years 109 (47.4) 207 (48.0) Matched
Time to diagnosis, y, n (%)
 <5 80 (34.8)
 ≥5 150 (65.2)
Age at menarche, y, n (%)
 <13 72 (35.0) 145 (36.0)
 ≥13 134 (65.0) 258 (64.0) 0.95
 Unknown, n (% of total missing) 24 (10.4) 29 (6.7)
Body Mass Index, kg/m2, n (%)
 <25 115 (53.5) 204 (49.8)
 ≥25 100 (46.5) 206 (50.2) 0.53
 Unknown, n (% of total missing) 15 (6.5) 22 (5.1)
Menopausal status at baseline, n (%)
 Premenopausal 86 (37.6) 161 (37.4)
 Postmenopausal 143 (62.4) 270 (62.6) Matched
Family history of breast or ovarian cancer, n (%)
 No 125 (77.6) 270 (84.9)
 Yes 36 (23.4) 48 (15.1) 0.07
 Unknown a, n (% of total missing) 69 (30.0) 114 (26.4)
Parity, n (%)
 Nulliparous 45 (22.5) 70 (17.5)
 Parous 155 (77.5) 331 (82.5) 0.17
 Unknown, n (% of total missing) 30 (13.0) 31 (7.2)
Age at first full term pregnancy b, y, n (%)
 < 25 years 45 (45.5) 95 (45.2)
 ≥ 25 years 54 (54.5) 115 (54.8) 0.78
 Unknown, n (% of total missing) 56 (36.1) 121 (36.6)
Use of oral contraceptives, n (%)
 Never 139 (69.8) 237 (64.4)
 Past 60 (30.2) 131 (35.6) 0.26
 Unknown, n (% of total missing) 31 (13.5) 64 (14.8)
Histology, n (%)
 Serous 120 (52.2)
 Endometrioid 30 (13.0)
 Clear cell 16 (7.0)
 Mucinous 22 (10.0)
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Characteristics Cases (N=230) Controls (N=432) p-value
 Undifferentiated 8 (3.5)
 Not Otherwise Specified 21 (9.1)
 Unknown 13 (5.7)
Prolactin, ng/mL, median (25th, 75th) 15.6 (8.5, 29.7) 14.8 (8.1, 29.8) 0.39
aVariable is not available from the ORDET cohort (41 cases and 82 controls)
bAmong ever parous women
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